CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.010
+0.020 (1.01%)
At close: Oct 1, 2025, 4:00 PM EDT
2.040
+0.030 (1.49%)
After-hours: Oct 1, 2025, 4:17 PM EDT
CytoMed Therapeutics Employees
CytoMed Therapeutics had 43 employees as of December 31, 2024. The number of employees increased by 9 or 26.47% compared to the previous year.
Employees
43
Change (1Y)
9
Growth (1Y)
26.47%
Revenue / Employee
n/a
Profits / Employee
-$67,065
Market Cap
23.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 9 | 26.47% |
| Dec 31, 2023 | 34 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GDTC News
- 4 weeks ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 6 weeks ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 2 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 5 months ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 8 months ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 9 months ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
- 1 year ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewsWire